UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Annals of oncology, 2016-10, Vol.27 (10), p.1928-1940

2016

Volltextzugriff (PDF)

T cell anergy and costimulation

Immunological reviews, 2003-04, Vol.192 (1), p.161-180

2003

Volltextzugriff (PDF)

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

Annals of oncology, 2018-10, Vol.29, p.viii290-viii290

2018

Volltextzugriff (PDF)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours

British journal of cancer, 2005-07, Vol.93 (1), p.54-59

2005

Volltextzugriff (PDF)

CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression

The Journal of immunology (1950), 2000-01, Vol.164 (1), p.144-151

2000

Volltextzugriff (PDF)

Sexuality and Cancer: Conversation Comfort Zone

The oncologist (Dayton, Ohio), 2000-08, Vol.5 (4), p.336-344

2000

Volltextzugriff (PDF)

Dominant‐negative p53 can restore tumorigenicity of L‐929 cells in immunocompetent mice

International journal of cancer, 1995-11, Vol.63 (4), p.576-583

1995

Volltextzugriff (PDF)

Helper T cell anergy : from biochemistry to cancer pathophysiology and therapeutics

Journal of molecular medicine (Berlin, Germany), 2001-01, Vol.78 (12), p.673-683

2001

Volltextzugriff (PDF)

Mouse embryo fibroblasts transformed by activated ras or dominant‐negative p53 express cross‐reactive tumor rejection antigens

International journal of cancer, 1995-06, Vol.61 (6), p.887-894

1995

Volltextzugriff (PDF)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

OncoTargets and therapy, 2014-01, Vol.7 (default), p.969-983

2014

Volltextzugriff (PDF)

Differential Localization and Function of ADP-Ribosylation Factor-6 in Anergic Human T Cells: A Potential Marker for Their Identification

The Journal of immunology (1950), 2003-08, Vol.171 (4), p.1691-1696

2003

Volltextzugriff (PDF)

A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2564-2564

2011

Volltextzugriff (PDF)

Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4527-4527

2010

Volltextzugriff (PDF)

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3035-3035

2011

Volltextzugriff (PDF)

Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5036-5036

2009

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-11, Vol.11 (21), p.7825-7833

2005

Volltextzugriff (PDF)

Effect of proton pump inhibitor co-medication on imatinib disposition: A healthy volunteer study

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2503-2503

2009

Volltextzugriff (PDF)

Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e16086-e16086

2009

Volltextzugriff (PDF)

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Tumor Antigens Encoded by Oncogenes and the Impact of Oncogenes upon the Immune Response

Cellular Immunology, 1996-05, Vol.170 (1), p.1-10

1996

Volltextzugriff (PDF)

Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5148-5148

2008

Volltextzugriff (PDF)

Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15603-15603

2007

Volltextzugriff (PDF)

A phase II trial of oxaliplatin and docetaxel in patients with androgen independent prostate cancer (AIPC) who have progressed to two prior regimens of chemotherapy

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15545-15545

2007

Volltextzugriff (PDF)

Abstract PD09-06: Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD09-06-PD09-06

2012

Volltextzugriff (PDF)

830PSynthetic DNA immunotherapy in biochemically relapsed prostate cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Englisch
(174)
Japanisch
(14)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(80)
Humans
(66)
Biological And Medical Sciences
(48)
Kinetics
(26)
Medical Sciences
(26)
Female
(25)
Male
(25)
Biochemistry & Molecular Biology
(24)
Fundamental And Applied Biological Sciences. Psychology
(22)
Adult
(20)
Oncology
(20)
Tetrahydrofolate Dehydrogenase - Metabolism
(20)
Analytical, Structural And Metabolic Biochemistry
(18)
Enzymes And Enzyme Inhibitors
(18)
Animals
(17)
Middle Aged
(17)
Oxidoreductases
(16)
Aged
(15)
Pharmacology. Drug Treatments
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

T cell anergy and costimulation

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours

CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression

Sexuality and Cancer: Conversation Comfort Zone

Dominant‐negative p53 can restore tumorigenicity of L‐929 cells in immunocompetent mice

Helper T cell anergy : from biochemistry to cancer pathophysiology and therapeutics

Mouse embryo fibroblasts transformed by activated ras or dominant‐negative p53 express cross‐reactive tumor rejection antigens

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

Differential Localization and Function of ADP-Ribosylation Factor-6 in Anergic Human T Cells: A Potential Marker for Their Identification

A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa)

Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase

Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Effect of proton pump inhibitor co-medication on imatinib disposition: A healthy volunteer study

Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Tumor Antigens Encoded by Oncogenes and the Impact of Oncogenes upon the Immune Response

Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial

Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer

A phase II trial of oxaliplatin and docetaxel in patients with androgen independent prostate cancer (AIPC) who have progressed to two prior regimens of chemotherapy

Abstract PD09-06: Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)

830PSynthetic DNA immunotherapy in biochemically relapsed prostate cancer

Suchergebnisse filtern